Aduro BioTech (NASDAQ:ADRO) received a $15.00 price objective from research analysts at Oppenheimer in a report issued on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price target points to a potential upside of 91.08% from the stock’s previous close.

Several other analysts have also weighed in on the company. BidaskClub lowered Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, William Blair restated an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Aduro BioTech currently has an average rating of “Buy” and an average target price of $19.14.

Shares of Aduro BioTech (ADRO) traded down $0.35 on Monday, hitting $7.85. The stock had a trading volume of 364,662 shares, compared to its average volume of 407,946. Aduro BioTech has a twelve month low of $6.01 and a twelve month high of $14.05.

Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The company had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. During the same quarter in the previous year, the company posted ($0.54) EPS. The business’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts predict that Aduro BioTech will post -1.28 earnings per share for the current fiscal year.

In other Aduro BioTech news, CEO Stephen T. Isaacs sold 16,400 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $7.96, for a total value of $130,544.00. Following the sale, the chief executive officer now owns 190,321 shares in the company, valued at $1,514,955.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Stephen T. Isaacs sold 40,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $10.78, for a total value of $431,200.00. Following the completion of the sale, the chief executive officer now owns 213,921 shares in the company, valued at approximately $2,306,068.38. The disclosure for this sale can be found here. Insiders have sold a total of 264,480 shares of company stock worth $2,484,317 in the last 90 days. 6.60% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in ADRO. Vanguard Group Inc. increased its stake in Aduro BioTech by 2.1% in the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock worth $25,617,000 after purchasing an additional 48,840 shares during the period. Geode Capital Management LLC increased its stake in Aduro BioTech by 6.0% in the first quarter. Geode Capital Management LLC now owns 262,809 shares of the biotechnology company’s stock worth $2,825,000 after purchasing an additional 14,946 shares during the period. Renaissance Technologies LLC increased its stake in Aduro BioTech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after purchasing an additional 160,800 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Aduro BioTech by 5.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock worth $1,560,000 after purchasing an additional 7,812 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in shares of Aduro BioTech during the 2nd quarter worth $408,000. Institutional investors and hedge funds own 45.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/11/aduro-biotech-adro-pt-set-at-15-00-by-oppenheimer.html.

Aduro BioTech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Analyst Recommendations for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.